Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 4/20 | 0.81 |
| ▸ | AURKB | Q96GD4 | 15/20 | 0.61 |
| ▸ | AURKA | O14965 | 14/20 | 0.61 |
| ▸ | LCK | P06239 | 4/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.41 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.37 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8241428 | 0.90 | CHEK1 (1.00) | CHEK1AURKBAURKALCKIRAK4 | |
| SCHEMBL13955026 | 0.88 | CHEK1 (0.63) | CHEK1AURKBAURKALCKIRAK4 | |
| SCHEMBL12473563 | 0.87 | CHEK1 (0.81) | CHEK1AURKBAURKALCKIRAK4 | |
| SCHEMBL14507696 | 0.85 | CHEK1 (0.77) | CHEK1AURKBAURKALCKIRAK4 | |
| SCHEMBL14538629 | 0.84 | CHEK1 (0.66) | CHEK1AURKBAURKALCKPTK6 | |
| SCHEMBL12473567 | 0.83 | CHEK1 (0.77) | CHEK1AURKBAURKALCKIRAK4 | |
| SCHEMBL14507674 | 0.83 | CHEK1 (0.67) | CHEK1AURKBAURKAPTK6 | |
| SCHEMBL12473340 | 0.82 | CHEK1 (0.71) | CHEK1AURKBAURKALCKIRAK4 | |
| SCHEMBL14507562 | 0.82 | CHEK1 (0.75) | CHEK1AURKBAURKALCKPTK6 | |
| SCHEMBL12473570 | 0.82 | CHEK1 (0.68) | CHEK1AURKBAURKALCKIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217611-B1 | NOVEL MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2013-07-31 | — | — | EP | disclosed |
| US-20110183933-A1 | NOVEL MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2011-07-28 | — | — | US | disclosed |
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION | 2010-09-30 | — | — | US | disclosed |
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION | 2010-09-30 | — | — | US | disclosed |
| WO-2009061781-A1 | NOVEL MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2009-05-14 | — | — | WO | disclosed |
| WO-2007058942-A2 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | SCHERING CORPORATION | 2007-05-24 | — | — | US | disclosed |
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | SCHERING CORPORATION | 2007-05-24 | — | — | US | disclosed |
| WO-2007056468-A1 | METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105864-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-05-10 | — | — | US | disclosed |
| US-20070105864-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183933-A1 | NOVEL MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS | CDC25C, CHEK1, CDC25A | CHEK1 2/4885AURKB 27/4885AURKA 40/4885 |
| US-20100249030-A1 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | AURKC, AURKA, AURKB | CHEK1 61/4885AURKB 3/4885AURKA 2/4885 |
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | CHEK1, CHEK2, CDKN1A | CHEK1 1/4885AURKB 138/4885AURKA 41/4885 |
| US-20070105864-A1 | Methods for inhibiting protein kinases | PIM1, PIM2, PIM3 | CHEK1 27/4885AURKB 24/4885AURKA 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.